{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:11:46Z","timestamp":1789431106779,"version":"build-2803163510"},"reference-count":52,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,27]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Large B-cell lymphoma (LBCL) patients failing anti-CD19 chimeric antigen receptor (CAR) T-cell therapy exhibit poor prognosis. Most progressions\/relapses occur within 3 months from infusion whereas only a few events occur thereafter (late failure, [LF]). We analyze features, treatments, and outcomes of patients with LF from DESCAR-T, a nationwide registry collecting real-life data for patients treated with approved CAR T-cell therapy in France. Between July 2018 and March 2024, 298 (39.9%) LBCL LF patients (median age, 62 years [range, 18-79]; male, 61.7%) were collected from DESCAR-T. Most patients had diffuse LBCL (n = 205 [68.8%]), advanced stage disease (84.6%), and age-adjusted International Prognostic Index of 2 to 3 (59.3%) at CAR T-cell eligibility. After failure, 76.5% of patients received a systemic therapy and overall response rate was 22.6% (complete response, 18%). At a median follow-up since first LF event of 13.8 months (95% confidence interval [CI], 12.1-15.4), the median overall survival and progression-free survival 2 (PFS-2) were 4.4 (95% CI, 3.8-5.8) and 13.2 (95% CI, 9.6-18) months, respectively. Compared with chemotherapy (hazard ratio [HR], 0.350; 95% CI, 0.193-0.633) and with pooled other treatment groups (HR, 0.483; 95% CI, 0.290-0.805), salvage treatment with bispecific antibodies (bsAb) after CAR T-cell failure showed better PFS-2. Radiotherapy obtained prolonged responses in some patients with 12-month PFS-2 of 41.5% (95% CI, 22.5-59.5). This work is, to our knowledge, the first study describing LBCL patients with LF after CAR T-cells. bsAb seem to be more effective compared with other strategies in the LF setting and this should be considered in the design of new clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016727","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T20:15:59Z","timestamp":1761164159000},"page":"392-401","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["Late failure of aggressive B-cell lymphoma after CAR T-cell therapy: a LYSA study from the DESCAR-T registry"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-0695-3480","authenticated-orcid":false,"given":"Federico","family":"Erbella","sequence":"first","affiliation":[{"name":"1Hemato-Oncology Department, Assistance Publique\u2013H\u00f4pitaux de Paris, Saint-Louis Hospital, Paris University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2694-7510","authenticated-orcid":false,"given":"Emmanuel","family":"Bachy","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Lyon-Sud Hospital, Oullins-Pierre-B\u00e9nite, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0659-9635","authenticated-orcid":false,"given":"Guillaume","family":"Cartron","sequence":"additional","affiliation":[{"name":"3Hematology Department, Centre Hospitalier Universitaire Montpellier, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Gat","sequence":"additional","affiliation":[{"name":"4The Lymphoma Academic Research Organisation, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Manson","sequence":"additional","affiliation":[{"name":"5Department of Hematology, University Hospital of Rennes, Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3714-9824","authenticated-orcid":false,"given":"Franck","family":"Morschhauser","sequence":"additional","affiliation":[{"name":"6Hematology Department, Lille University Hospital, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8998-3039","authenticated-orcid":false,"given":"Francois-Xavier","family":"Gros","sequence":"additional","affiliation":[{"name":"7Clinical Hematology and Cell Therapy Department, Centre Hospitalier Universitaire Bordeaux, Merignac, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Roulin","sequence":"additional","affiliation":[{"name":"8Service H\u00e9mopathies Lympho\u00efdes, H\u00f4pital Henri Mondor, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7600-3329","authenticated-orcid":false,"given":"Benoit","family":"Tessoulin","sequence":"additional","affiliation":[{"name":"9Service d'H\u00e9matologie Clinique, Centre Hospitalier Universitaire de Nantes, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Bories","sequence":"additional","affiliation":[{"name":"10Hematology Department, Oncopole Toulouse, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9438-621X","authenticated-orcid":false,"given":"Olivier","family":"Tournilhac","sequence":"additional","affiliation":[{"name":"11Service de Th\u00e9rapie Cellulaire et d'H\u00e9matologie Clinique Adulte, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Ricard","sequence":"additional","affiliation":[{"name":"12Department of Clinical Hematology and Cellular Therapy, Saint Antoine Hospital, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris, France"},{"name":"13Mixed Research Unit, INSERM 938, Sorbonne University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8755-5591","authenticated-orcid":false,"given":"St\u00e9phanie","family":"Guidez","sequence":"additional","affiliation":[{"name":"14Oncology-Hematology and Cell Therapy Department, Centre Hospitalier Universitaire, Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7791-0470","authenticated-orcid":false,"given":"Sylvain","family":"Choquet","sequence":"additional","affiliation":[{"name":"15Department of Hematology, La Pitie Salpetriere Hospital, Assistance Publique\u2013H\u00f4pitaux de Paris Sorbonne Universite, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1156-8983","authenticated-orcid":false,"given":"Rene-Olivier","family":"Casasnovas","sequence":"additional","affiliation":[{"name":"16Department of Hematology, Centre Hospitalier Universitaire de Dijon, Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0771-683X","authenticated-orcid":false,"given":"Gabriel","family":"Brisou","sequence":"additional","affiliation":[{"name":"17Department of Hematology, Institut Paoli-Calmettes, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Campidelli","sequence":"additional","affiliation":[{"name":"18Department of Hematology, Centre Hospitalier R\u00e9gional Universitaire Nancy, H\u00f4pitaux de Brabois, Vandoeuvre-l\u00e8s-Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Castilla-Llorente","sequence":"additional","affiliation":[{"name":"19Hematology Department, Institut Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Jardin","sequence":"additional","affiliation":[{"name":"20Department of Clinical Hematology, Centre Henri-Becquerel, Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7651-9189","authenticated-orcid":false,"given":"Emmanuel","family":"Gyan","sequence":"additional","affiliation":[{"name":"21Service d'h\u00e9matologie et Th\u00e9rapie Cellulaire, Centre Hospitalier Universitaire de Tours, Tours, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blandine","family":"Guffroy","sequence":"additional","affiliation":[{"name":"22Department of Hematology, Institute for Cancer Strasbourg-Europe, Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5593-7761","authenticated-orcid":false,"given":"Julie","family":"Abraham","sequence":"additional","affiliation":[{"name":"23Hematology Department, Centre Hospitalier Universitaire Dupuytren, Limoges, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Decroocq","sequence":"additional","affiliation":[{"name":"24Service d'H\u00e9matologie Clinique, Assistance Publique-H\u00f4pitaux de Paris, Centre-Universit\u00e9 de Paris, H\u00f4pital Cochin, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrien","family":"Chauchet","sequence":"additional","affiliation":[{"name":"25Department of Hematology, University Hospital of Besan\u00e7on, Besan\u00e7on, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magalie","family":"Joris","sequence":"additional","affiliation":[{"name":"26Department of Clinical Hematology and Cell Therapy, Centre Hospitalier Universitaire Amiens, Amiens, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Claves","sequence":"additional","affiliation":[{"name":"27Hematology Department, Centre Hospitalier Universitaire Grenobles, Grenobles, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0796-7914","authenticated-orcid":false,"given":"Sylvain","family":"Carras","sequence":"additional","affiliation":[{"name":"27Hematology Department, Centre Hospitalier Universitaire Grenobles, Grenobles, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00eblle","family":"Guillerm","sequence":"additional","affiliation":[{"name":"28Department of Hematology, Brest University Hospital, Brest, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4460-5939","authenticated-orcid":false,"given":"Micha\u00ebl","family":"Loschi","sequence":"additional","affiliation":[{"name":"29Hematology Department, University Hospital of Nice, Cote d'Azur University, Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[{"name":"30Hematology Department, Necker Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Taguy-Schimidt","sequence":"additional","affiliation":[{"name":"31Blood Diseases Department, France Federation University Hospital Grand Ouest Against Leukemia, Angers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9840-2128","authenticated-orcid":false,"given":"Steven","family":"Le Gouill","sequence":"additional","affiliation":[{"name":"32Service d\u2019H\u00e9matologie Clinique, Institut Curie, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1729-8213","authenticated-orcid":false,"given":"Roch","family":"Houot","sequence":"additional","affiliation":[{"name":"5Department of Hematology, University Hospital of Rennes, Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9001-573X","authenticated-orcid":false,"given":"Roberta","family":"Di Blasi","sequence":"additional","affiliation":[{"name":"1Hemato-Oncology Department, Assistance Publique\u2013H\u00f4pitaux de Paris, Saint-Louis Hospital, Paris University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,1,15]]},"reference":[{"issue":"5","key":"2026012709315511000_bib1","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1182\/blood.2023020854","article-title":"Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001","volume":"143","author":"Abramson","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2026012709315511000_bib2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2026012709315511000_bib3","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1182\/blood-2021-148078","article-title":"Long-term (\u22654 year and \u22655 year) overall survival (OS) by 12- and 24-month event-free survival (EFS): an updated analysis of ZUMA-1, the pivotal study of axicabtagene ciloleucel (axi-cel) in patients (pts) with refractory large B-cell lymphoma (LBCL)","volume":"138","author":"Jacobson","year":"2021","journal-title":"Blood"},{"issue":"2","key":"2026012709315511000_bib4","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with axicabtagene ciloleucel in large B-cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N Engl J Med"},{"issue":"10343","key":"2026012709315511000_bib5","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"issue":"8","key":"2026012709315511000_bib6","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(22)00339-4","article-title":"Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study","volume":"23","author":"Sehgal","year":"2022","journal-title":"Lancet Oncol"},{"issue":"10","key":"2026012709315511000_bib7","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1038\/s41591-023-02572-5","article-title":"Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial","volume":"29","author":"Houot","year":"2023","journal-title":"Nat Med"},{"issue":"3","key":"2026012709315511000_bib8","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/bjh.18209","article-title":"A national service for delivering CD19 CAR-Tin large B-cell lymphoma \u2013 the UK real-world experience","volume":"198","author":"Kuhnl","year":"2022","journal-title":"Br J Haematol"},{"issue":"9","key":"2026012709315511000_bib9","doi-asserted-by":"crossref","first-page":"581.e1","DOI":"10.1016\/j.jtct.2022.05.026","article-title":"Real-world evidence of axicabtagene ciloleucel for the treatment of large B cell lymphoma in the United States","volume":"28","author":"Jacobson","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"suppl 1","key":"2026012709315511000_bib10","doi-asserted-by":"crossref","first-page":"5138","DOI":"10.1182\/blood-2023-180241","article-title":"Real world data of axicabtagene ciloleucel as second line therapy for patients with large B cell lymphoma: first results of a Lysa study from the French Descar-T registry","volume":"142","author":"Brisou","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2026012709315511000_bib11","doi-asserted-by":"crossref","first-page":"4886","DOI":"10.1182\/blood-2023-188473","article-title":"Second vs third line treatment with axicabtagene ciloleucel for large B cell lymphoma \u2013 a real-life national multicenter retrospective cohort study with propensity score matching","volume":"142","author":"Fridberg","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2026012709315511000_bib12","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3324\/haematol.2022.280805","article-title":"Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma","volume":"108","author":"Kwon","year":"2023","journal-title":"Haematologica"},{"issue":"10","key":"2026012709315511000_bib13","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1002\/cam4.3881","article-title":"Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma","volume":"10","author":"Iacoboni","year":"2021","journal-title":"Cancer Med"},{"issue":"27","key":"2026012709315511000_bib14","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T Consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026012709315511000_bib15","first-page":"349","article-title":"GLA\/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany","volume":"140","author":"Bethge","year":"2022","journal-title":"Blood"},{"issue":"24","key":"2026012709315511000_bib16","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1182\/blood.2022016945","article-title":"Outcomes of patients with aggressive B-Cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis","volume":"140","author":"Di Blasi","year":"2022","journal-title":"Blood"},{"issue":"21","key":"2026012709315511000_bib17","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"2026012709315511000_bib18","doi-asserted-by":"crossref","first-page":"77.e1","DOI":"10.1016\/j.jtct.2023.10.017","article-title":"Real-world outcomes with chimeric antigen receptor T cell therapies in large B cell lymphoma: a systematic review and meta-analysis","volume":"30","author":"Jacobson","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"suppl 1","key":"2026012709315511000_bib19","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1182\/blood-2023-180242","article-title":"Multicenter, real-world study in patients with R\/R large B-cell lymphoma (LBCL) who received lisocabtagene maraleucel (liso-cel) in the United States (US)","volume":"142","author":"Crombie","year":"2023","journal-title":"Blood"},{"issue":"10","key":"2026012709315511000_bib20","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"issue":"26","key":"2026012709315511000_bib21","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"2026012709315511000_bib22","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1182\/bloodadvances.2021005807","article-title":"Early FDG-PET response predicts CAR-T failure in large B-cell lymphoma","volume":"6","author":"Kuhnl","year":"2022","journal-title":"Blood Adv"},{"issue":"12","key":"2026012709315511000_bib23","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1182\/bloodadvances.2022008240","article-title":"Peri\u2013CAR-T practice patterns and survival predictors for all CAR-T patients and post\u2013CAR-T failure in aggressive B-NHL","volume":"7","author":"Zurko","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"2026012709315511000_bib24","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41375-022-01739-2","article-title":"Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma","volume":"37","author":"Alarcon Tomas","year":"2022","journal-title":"Leuk"},{"issue":"13","key":"2026012709315511000_bib25","first-page":"1832","article-title":"Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy","volume":"137","author":"Spiegel","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2026012709315511000_bib26","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1182\/blood-2023-184942","article-title":"The post-CAR prognostic index (PC-PI): a new prognostic score to predict overall survival in large B-cell lymphoma patients progressing after chimeric antigen receptor T-cell therapy","volume":"142","author":"Iacoboni","year":"2023","journal-title":"Blood"},{"issue":"3","key":"2026012709315511000_bib27","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.clml.2016.11.001","article-title":"Late relapses after high-dose chemotherapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphoma in the rituximab era","volume":"17","author":"Hunter","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"21","key":"2026012709315511000_bib28","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1200\/JCO.19.00014","article-title":"Late relapses in patients with diffuse large b-cell lymphoma treated with immunochemotherapy","volume":"37","author":"Wang","year":"2019","journal-title":"J Clin Oncol"},{"issue":"8","key":"2026012709315511000_bib29","doi-asserted-by":"crossref","first-page":"E209","DOI":"10.1002\/ajh.25505","article-title":"Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy","volume":"94","author":"Chow","year":"2019","journal-title":"Am J Hematol"},{"issue":"27","key":"2026012709315511000_bib30","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"S2","key":"2026012709315511000_bib31","doi-asserted-by":"crossref","first-page":"hon.87_2879","DOI":"10.1002\/hon.87_2879","article-title":"Outcome of large B-cell lymphoma patients failing Cd19 targeted Car-T therapy","volume":"39","author":"Kuhnl","year":"2021","journal-title":"Hematol Oncol"},{"issue":"suppl 1","key":"2026012709315511000_bib32","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1182\/blood-2021-148751","article-title":"Outcomes of large B-cell lymphoma patients by post CAR-T salvage regimen at a single institution","volume":"138","author":"Sigmund","year":"2021","journal-title":"Blood"},{"issue":"24","key":"2026012709315511000_bib33","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"issue":"12","key":"2026012709315511000_bib34","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell\u2013engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J Clin Oncol"},{"issue":"S2","key":"2026012709315511000_bib35","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/hon.3163_94","article-title":"Subcutaneous epcoritamab induces deep, durable complete remissions in relapsed\/refractory large b-cell lymphoma: longer follow-up from the pivotal epcore NHL-1 trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"Hematol Oncol"},{"issue":"suppl 1","key":"2026012709315511000_bib36","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1182\/blood-2023-173951","article-title":"Glofitamab monotherapy in relapsed or refractory large B-cell lymphoma: extended follow-up from a pivotal phase II study and subgroup analyses in patients with prior chimeric antigen receptor T-cell therapy and by baseline total metabolic tumor volume","volume":"142","author":"Hutchings","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2026012709315511000_bib37","doi-asserted-by":"crossref","first-page":"4461","DOI":"10.1182\/blood-2023-181602","article-title":"Odronextamab demonstrates durable complete responses in patients with diffuse large B-cell lymphoma (DLBCL) progressing after CAR-T therapy: outcomes from the ELM-1 study","volume":"142","author":"Crombie","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2026012709315511000_bib38","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/bjh.19057","article-title":"Outcome after chimeric antigen receptor (CAR) T-cell therapy failure in large B-cell lymphomas","volume":"204","author":"Dodero","year":"2024","journal-title":"Br J Haematol"},{"issue":"suppl 1","key":"2026012709315511000_bib39","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2023-177703","article-title":"Glofitamab monotherapy in patients with non-Hodgkin B-cell lymphoma after failing CAR T-cell infusion: primary analysis of the BiCAR study, a phase II Lysa study","volume":"142","author":"Sesques","year":"2023","journal-title":"Blood"},{"issue":"7","key":"2026012709315511000_bib52","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/s43018-025-00941-2","article-title":"Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA study","volume":"6","author":"Cartron","year":"2025","journal-title":"Nat Cancer"},{"issue":"S3","key":"2026012709315511000_bib40","doi-asserted-by":"crossref","first-page":"e55140cd","DOI":"10.1097\/01.HS9.0000971360.55140.cd","article-title":"High complete metabolic response rates with epcoritamab + r-chop in previously untreated (1l) patients with high-risk diffuse large b-cell lymphoma, including double\/triple-hit: epcore nhl-2 update [abstract]","volume":"7","author":"Roost Clausen","year":"2023","journal-title":"HemaSphere"},{"issue":"suppl 1","key":"2026012709315511000_bib41","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1182\/blood-2023-174081","article-title":"Glofitamab plus R-CHOP induces high response rates with a manageable safety profile in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): a 12-month analysis from a phase Ib study","volume":"142","author":"Topp","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2026012709315511000_bib42","doi-asserted-by":"crossref","first-page":"4460","DOI":"10.1182\/blood-2023-174213","article-title":"Glofitamab plus polatuzumab vedotin continues to demonstrate frequent and durable responses and has a manageable safety profile in patients with \u22652L relapsed\/refractory DLBCL, including HGBCL, and in patients with prior CAR T-cell therapy: updated results from a phase Ib\/II study","volume":"142","author":"Hutchings","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2026012709315511000_bib43","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1182\/blood-2023-180047","article-title":"Efficacy of subcutaneous epcoritamab vs tisa-cel in R\/R LBCL CAR T-naive and CAR T-eligible patients: an indirect comparison","volume":"142","author":"Salles","year":"2023","journal-title":"Blood"},{"issue":"S3","key":"2026012709315511000_bib44","doi-asserted-by":"crossref","first-page":"e006348e","DOI":"10.1097\/01.HS9.0000971512.00634.8e","article-title":"Efficacy of subcutaneous epcoritamab vs axi-cel in r\/r dlbcl car t-naive and car t-eligible patients: an indirect comparison [abstract]","volume":"7","author":"Thieblemont","year":"2023","journal-title":"HemaSphere"},{"issue":"suppl 1","key":"2026012709315511000_bib45","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1182\/blood-2023-185035","article-title":"Efficacy of chimeric antigen receptor T-cell therapy is not impaired by previous bispecific antibody treatment in patients with large B-cell lymphoma","volume":"142","author":"Iacoboni","year":"2023","journal-title":"Blood"},{"issue":"20","key":"2026012709315511000_bib46","doi-asserted-by":"crossref","first-page":"5371","DOI":"10.1182\/bloodadvances.2024013726","article-title":"Outcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR-T-cells","volume":"8","author":"Camus","year":"2024","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2026012709315511000_bib47","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/blood-2020-136279","article-title":"Lenalidomide enhance CAR T-cells response in patients with refractory\/relapsed large B cell lymphoma experiencing progression after infusion","volume":"136","author":"Thieblemont","year":"2020","journal-title":"Blood"},{"key":"2026012709315511000_bib48","doi-asserted-by":"crossref","first-page":"109580","DOI":"10.1016\/j.radonc.2023.109580","article-title":"Potential synergy between radiotherapy and CAR T-cells - a multicentric analysis of the role of radiotherapy in the combination of CAR T cell therapy","volume":"183","author":"Fan","year":"2023","journal-title":"Radiother Oncol"},{"issue":"4","key":"2026012709315511000_bib49","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1002\/jha2.757","article-title":"PET-based radiomics signature can predict durable responses to CAR T-cell therapy in patients with large B-cell lymphoma","volume":"4","author":"Ligero","year":"2023","journal-title":"eJHaem"},{"issue":"27","key":"2026012709315511000_bib50","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1200\/JCO.21.00377","article-title":"Monitoring of circulating tumor DNA improves early relapse detection after axicabtagene ciloleucel infusion in large B-cell lymphoma: results of a prospective multi-institutional trial","volume":"39","author":"Frank","year":"2021","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2026012709315511000_bib51","doi-asserted-by":"crossref","first-page":"7457","DOI":"10.1182\/blood-2022-170629","article-title":"Circulating tumor DNA correlation with lymphoma response and survival outcomes at multiple time points of anti - CD19 CAR T cell therapy","volume":"140","author":"Caimi","year":"2022","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/2\/392\/2498026\/blooda_adv-2025-016727-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/2\/392\/2498026\/blooda_adv-2025-016727-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T14:32:07Z","timestamp":1769524327000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/2\/392\/547866\/Late-failure-of-aggressive-B-cell-lymphoma-after"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,15]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016727","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1,27]]},"published":{"date-parts":[[2026,1,15]]}}}